TH-19P01

TH-19P01 is a proprietary **targeting peptide** developed by Theratechnologies for use in **peptide-drug conjugates** directed against **sortilin-positive cancers**. The peptide binds **sortilin receptor 1**, a cell-surface receptor overexpressed in multiple solid tumors, and functions primarily as a **tumor-targeting and internalization moiety** rather than as a standalone cytotoxic agent. TH-19P01 itself is not described as having intrinsic anticancer activity; instead, it is conjugated to payloads such as docetaxel, doxorubicin, or curcumin to generate investigational targeted oncology agents including TH1902, TH1904, and TH1901 for cancers such as triple-negative breast cancer, ovarian cancer, and endometrial cancer.

Other names

SORT1-binding peptideSORT-1-binding peptideSORT 1-binding peptide